Talaris Therapeutics, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 73.89 million compared to USD 47.83 million a year ago. Basic loss per share from continuing operations was USD 17.9 compared to USD 16.4 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15 USD | -1.64% | -4.88% | -42.70% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-42.70% | 391M | |
+8.29% | 113B | |
+10.21% | 106B | |
+0.41% | 22.27B | |
-11.90% | 22.22B | |
-5.99% | 19.43B | |
-37.36% | 17.87B | |
-5.17% | 17.24B | |
+7.70% | 14.29B | |
+37.65% | 12.52B |
- Stock Market
- Equities
- TRML Stock
- News Tourmaline Bio, Inc.
- Talaris Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022